AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer
SINGAPORE, May 18, 2026 /PRNewswire/ -- AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care across nine Asia markets, a first...
The 28th China Beijing International High-Tech Expo Opens
BEIJING, May 9, 2026 /PRNewswire/ -- This is a news report from CCTV.com: The 28th China Beijing International High-Tech Expo (hereinafter referred to as CHITEC) is held at the China National Convention Center in Beijing from May 8 to 10. With the...
The 28th China Beijing International High-Tech Expo Grand Opening Soon
Technology Leads the Way, Innovation Shares the Future BEIJING, May 2, 2026 /PRNewswire/ -- A report from CCTV.com: From May 8 to 10, 2026, the 28th China Beijing International High-Tech Expo (hereinafter referred to as CHITEC) will be held at the...
SKF commits to a sovereign AI future through strategic partnership with Sferical AI
GOTHENBURG, Sweden, April 30, 2026 /PRNewswire/ -- SKF commits to joining Sferical AI – a company co-founded by AstraZeneca, Ericsson, Saab, SEB and Wallenberg Investments – as a strategic compute partner. By securing dedicated capacity on one of...
Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer
Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading...
Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...
Keymed Biosciences Announces 2025 Annual Results and Business Updates
BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization. Revenue Leaps Forward,...
Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 19, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in...
The 15th Five-Year Plan featuring opening up: China and the world sharing the future
BEIJING, March 7, 2026 /PRNewswire/ -- A news report from China.org.cn on China's new efforts on further opening up: The 15th Five-Year Plan featuring opening up: China and the world sharing the future The year 2026 marks the beginning of China's...
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology...